Work at Hangzhou Highlightll Pharmaceutical Co. Ltd. has led to the development of tyrosine-protein kinase JAK1, JAK2 and non-receptor tyrosine-protein kinase TYK2 inhibitors.
Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Researchers from the University of Stellenbosch in South Africa are seeking protection for a simple and user-friendly point-of-care device for diagnosing tuberculosis. Their electrochemical lateral flow device merges lateral flow device technology and electrochemical device technology by using porous electrodes that are capable of transporting electrolytic liquid and fluid sample.
Cytokinetics Inc. has disclosed fast skeletal muscle myosin inhibitors reported to be useful for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, spinal cord injury, limb girdle muscular dystrophy, stroke, tendinitis and tremor, among others.
Jawaharlal Nehru Centre for Advanced Scientific Research has divulged naphthalene monoimide compounds acting as modulators of liquid-liquid phase separation (LLPS) of tau protein reported to be useful for the treatment of traumatic encephalopathy, progressive supranuclear palsy, tauopathies, frontotemporal dementia and Alzheimer’s disease.
Hangzhou Highlightll Pharmaceutical Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammation, liver and metabolic disease, neuroinflammation, immunological, cardiovascular and renal disorders.
Jinyao Biotechnology (Tianjin) Co. Ltd. has synthesized glucocorticoid receptor (GR) agonists reported to be useful for the treatment of psoriasis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, eczema, allergic rhinitis and Crohn’s disease.
RSS
